ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Partial Responses To Zactima In Thyroid Cancer Trial

January 27, 2006

Michael Grever To Head DTP; Chabner’s Deputy Is Kaufman; Radiation Program To Be Split

April 5, 1991

In Congress: Societies, Advocates, Testify For Increases In Research Funding

February 13, 1998

Believers “Flout Fundamental Law Of Physics,” Park Says.

August 1, 2008

In Brief: Congressional Action Imminent On Cancer Ac Renewal, Hew Money Bills; Veto Threatened

September 8, 1978

In Brief: UICC Honors Center Director’s Efforts To Improve Cancer Control In India

March 13, 1998